logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Biogen Ma Inc.


USPTO Granted Patents = 267

% Expired Patents = 12.0



Trademarks = 37

Forward Citations = 987

Loading Chart...
Loading Chart...

432 inventors (with patents filed for the assignee):

goldMedal Bin Ma (35 out of 39 patents)

silverMedal Gnanasambandam Kumaravel (33 out of 60 patents)

bronzeMedal Kevin Guckian (30 out of 40 patents)

4.  Brian T Hopkins (24 out of 34 patents)

5.  Zhili Xin (21 out of 44 patents)

6.  Lei Zhang (18 out of 22 patents)

7.  Sha Mi (16 out of 34 patents)

8.  Timothy Raymond Chan (15 out of 18 patents)

9.  Meena Subramanyam (14 out of 16 patents)

10.  Tatiana Plavina (14 out of 14 patents)

11.  Jermaine Thomas (14 out of 21 patents)

12.  Edward Yin-Shiang Lin (13 out of 22 patents)

13.  Tracy J Jenkins (13 out of 19 patents)

14.  Arthur G Taveras (13 out of 72 patents)

15.  Joseph P Lyssikatos (12 out of 140 patents)


Core Competencies:
Autoimmune Diseases
Bruton's Tyrosine Kinase
Glycosylation Control
O-glycoprotein Inhibitors
Raman Spectroscopy
Alzheimer's Treatment
Neurofilament Protein
Drug Delivery
Cerebral Hemorrhage
Inflammation Treatment
SMN Protein
Biaryl Inhibitors

267 patents:

1. 12734236 - ANTI-VLA-4 ANTIBODIES (2026-09-15),
2. 12716899 - Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels (2026-08-25),
3. 12709621 - TYK2 INHIBITORS (2026-08-18),
4. 12692495 - Methods of preparing oligonucleotide compositions using ultrafiltration/diafiltration (2026-07-28),
5. 12685851 - Fluid catheter device for recording brain state (2026-07-21),
6. 12679882 - OPTIMIZED FACTOR VIII GENE (2026-07-14),
7. 12656353 - BIOMARKERS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (2026-06-16),
8. 12607638 - Methods of treating inflammatory and autoimmune diseases with natalizumab (2026-04-21),
9. 12605537 - Implantable medical device for use with or having recording electrode (2026-04-21),
10. 12570691 - PURIFICATION OF CHIMERIC FVIII MOLECULES (2026-03-10),
11. 12570631 - Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk (2026-03-10),
12. 12565504 - Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors (2026-03-03),
13. 12565500 - Substituted pyrrolo[1,2-b]pyridazines and pyrrolo[2,1-f][1,2,4]triazines as Btk inhibitors (2026-03-03),
14. 12551669 - Medical system including two access ports (2026-02-17),
15. 12522595 - Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2026-01-13),
Biogen is a global biotechnology company that focuses on the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. With a mission to transform the lives of patients and provide hope, Biogen strives to advance scientific knowledge and create innovative treatment options. Their dedication to breakthrough research, cutting-edge technology, and collaboration with healthcare professionals contributes to the improvement of patient outcomes worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Biogen Ma Inc.
267 Patents

#13 in Cambridge, MA

#98 in Massachusetts

#1,623 in US

#3,278 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Biogen Ma Inc.

Forward Citations = 987

432 inventors:

goldMedal Bin Ma (35 out of 39 patents)

silverMedal Gnanasambandam Kumaravel (33 out of 60 patents)

bronzeMedal Kevin Guckian (30 out of 40 patents)

4.  Brian T Hopkins (24 out of 34 patents)

5.  Zhili Xin (21 out of 44 patents)

Please report any incorrect information to [email protected]
Loading…